
Kirin Holdings Company, Limited
KNBWY
Updated: 22/09/2026, 23:27:35
Kirin Holdings Company, Limited, a diversified global conglomerate, was established in 1885 and maintains its headquarters in Tokyo, Japan. This entity operates across Japan and internationally, manufacturing and marketing a broad array of products. Its core activities are structured around four key divisions: Japan Beer and Spirits, Japan Non-Alcoholic Beverages, Oceania Integrated Beverages, and Pharmaceuticals. Kirin's extensive product portfolio encompasses alcoholic beverages such as beer (including happo-shu), wine, whiskey, and spirits, alongside soft drinks, dairy items, and fruit juices. Beyond beverages, the company is a developer and purveyor of pharmaceutical and biochemical goods. Its operations extend to managing various factories and theme parks, overseeing a chain of Kirin City beer pubs, and manufacturing specialized amino acids and nucleic acids for both pharmaceutical and industrial applications, including bulk pharmaceuticals. Additionally, Kirin crafts items such as margarine, jams, and honey. The company is also involved in the production and distribution of Coca-Cola products, other soft drinks, sake, and various food items. Furthermore, it manufactures and supplies Four Roses bourbon and functions as an insurance agency. Kirin Holdings underwent a name change in July 2007, having previously been recognized as Kirin Brewery Company, Limited.
No summaries found.
- Share price
- $18.04
- Market cap
- $14.40B
- Exchange
- OTC
- Currency
- USD
- CEO
- Yoshinori Isozaki
- Employees
- 31,144
- IPO date
- 17/03/1980
- Beta
- 0.041
- Last dividend
- $0.00
- Day range
- $18.04 – $18.17
- 52-week range
- $14.01 – $19.99
- 1-day performance
- 0.17%
- 1-year performance
- 28.77%
- Current drawdown (1Y)
- -9.75%
- CIK
- N/A
- CUSIP
- 497350306
- ISIN
- US4973503067
- Created
- 07/12/2025, 04:58:12
- Last update
- 22/09/2026, 23:27:35
Track Kirin Holdings Company, Limited with an AI analyst
See which prediction-market events move KNBWY, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
GlobeNewsWire • STOCK • 11/06/2026, 10:02:00
Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL
GlobeNewsWire • STOCK • 10/06/2026, 10:00:00
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
GlobeNewsWire • STOCK • 02/06/2026, 10:32:00
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
GlobeNewsWire • STOCK • 12/05/2026, 11:40:00
Kyowa Kirin stops development of skin condition treatment
Reuters • STOCK • 03/03/2026, 09:47:29
3 Reasons Growth Investors Will Love Kirin (KNBWY)
Zacks Investment Research • STOCK • 09/02/2026, 14:46:09
Is Kirin (KNBWY) Stock Undervalued Right Now?
Zacks Investment Research • STOCK • 09/02/2026, 11:40:47